
Popular Posts
-
Dear Doctor/Colleague The Novartis, a Swiss Multinational pharmaceutical company operating in India,has challenged the order of the Patent O...
-
Baje bhagat is a well known Sangi from Sisana village. His projection what he deserved could not be there because of caste biaes in Haryana....
-
GENDER ISSUES IN HEALTH IN HARYANA Dr. R.S. Dahiya Assoc.Prof, PGIMS, Rohtak. It is a well established fact the biologically women are a st...
-
Bina dahej key bayah karan aur karwawan haryana mai kadhey hokai nai ek nayari missal rachawan haryana mai-----
-
Gayak and activist saathi Gulab Singh is singing a folk song pon the theme.
-
The violence against women has increased so much in Haryana in recent years that the state has attained the dubious distinction of being amo...
-
Pre-Birth Elemination of Female & new paradigm of development in Haryana. The issue of missing girls and women in Haryana has gone to an...
Thursday, April 28, 2011
Thursday, May 15, 2008
Monday, January 14, 2008
BAJE BHAGAT
MAHARI KHETI
Baigaddi
Tuesday, January 8, 2008
Monday, December 31, 2007
PLANET EARTH CRISIS
The Rich-Poor Divide Widens Further
PLANET EARTH CRISIS DEEPENS
ONCE again, India’s ranking in the Human Development Index (HDI) has dropped. Last year, India ranked 126 amongst 177 countries. This year, the ranking has come down to 128, even behind Maldives. To be fair, however, India’s HDI value has grown marginally from 0.611 to 0.619. Yet, its lower rating is due to the fact that other developing countries have faired better. The report states: “While India is a high growth economy, the benefits have been unequally shared and there is a large human development backlog. Around 28 per cent of the population, some 320 million people live below the poverty line and three quarters of the poor are in rural areas.” With the continuing agrarian distress in the country, this only confirms what we have been stating in these columns regularly. Far from achieving “inclusive growth” as declared by the Eleventh Five Year Plan, two Indias are being created – the `shining’ and the `suffering’ – and the gap is widening.
The HDI is a summary measure monitoring long term progress in the average level of human development in three basic dimensions – a long and healthy life; access to knowledge; and, decent standard of living. These are measured by a series of quantitative data parameters.
The data in the report confirms the growing inequalities – between countries as well as within countries – between the rich and the poor in the phase of current globalisation. 40 per cent of world’s population living on less than $ 2 a day accounts for 5 per cent of global income while the richest 20 per cent accounts for three quarters of world income. More than 80 per cent of the world’s population lives in countries where income differentials are widening. Around ten million children die each year before the age of 5 and around 28 per cent of all children in the developing countries are undernourished.
This year’s HDR’s significance, however, lies in the fact that it has brought out an additional alarming dimension – climate change – which further accentuates this divide apart from threatening the very future of human civilisation. At the present rate the global temperature is expected to increase by 5 degrees Celsius in the 21st century, while the danger mark threatening life sustainability on the planet would be crossed at 2 degrees Celsius. If this is not arrested, then the worst sufferers would be 40 per cent of the world’s poor people – 2.6 billion.
Climate change occurs through the emission of greenhouse gases, mainly carbon dioxide that trap heat in the atmosphere. The current global release of such gases has exceeded the natural range of the last 650,000 years in the life of our planet. The main reason for this is the pattern of industrialisation, in pursuit of ever higher profits by capitalism, in the industrially-advanced countries. The carbon emission footprint of the USA is over 15 times that of India. If every person in the developing world were to have the same carbon footprint as one in USA or Canada, then the level of emissions would be 9 times higher than the limit required to sustain our planet.
Thus, the primary cause for bringing the world to such a disaster has been the predatory capriciousness of global capitalism. Not only have the developed countries enriched themselves at the expense of intensified exploitation of the developing world, but, ironically, the consequent climate change affects the people in the developing world most adversely.
Climate change will affect rainfall, temperature and water availability adversely affecting livelihood of billions dependent on agriculture in the world. Needless to add, India would be one of the worst sufferers. The melting of glaciers will affect the flows of river waters affecting the lives of billions of people. Particularly, the whole of South Asia would be affected with the retreat of the Himalayan glaciers. A 3-4 degree increase in the global temperature will displace millions due to flooding. The warming of the seas and land would lead to the extinction of one-third of our species.
The affects of such changes are already been felt. Some 262 million people had been adversely affected by climate disasters annually between 2000 and 2004. 98 per cent of these are in the developing countries. Out of every 1500 people affected, for instance, 1470 belong to the developing world while only one may belong to the industrially-developed countries. Such poor people are often forced to sell their productive assets or save on food, health and education, creating “life-long cycles of disadvantage”. Illustrating this, the report states: “Indian women born during a flood in the 1970s were 19 per cent less likely to have attended primary school.” Thus, the report warns: “Superimposing incremental climate change risks on (India’s) large human development deficit would compromise the ambition of inclusive growth.”
While the facts are startling and warrant immediate global attention and action, the proposals to tackle the situation have become controversial. The report prescribes a 50 per cent global reduction in greenhouse gas emissions by 2050 compared to the 1990 levels for a sustainable future. To achieve this, it suggests that the developed countries must cut their emissions by 30 per cent by 2020 growing to 80 per cent by 2050. The developing countries are being asked to reduce emissions by 20 per cent by 2050.
Under the Kyoto Protocol, which runs till 2012, the major thrust of reducing emissions was on the developed countries while the developing countries were exempted. This was naturally so because it is the developed world that is overwhelmingly responsible for triggering this climate change. True to its nature and with imperialist arrogance, the USA refused to ratify the Kyoto Protocol. This HDR report comes on the eve of a crucial summit on climate change at Bali which will deliberate and hopefully decide on these matters. Given US imperialism’s intransigence, it continues to refuse to take any responsibility for being the major plunderer of world’s resources and the largest carbon emitter.
Unlike this HDR report, which prescribes solutions on the basis of total global emissions, the Indian prime minister at the recent G-8 Summit in Germany proposed that per capita emissions must be the basis for a solution. For instance, India’s per capita emission is 17 times less than that of the USA. USA, today, emits around 20 tonnes per capita while India emits around one tonne per capita. Reducing 80 per cent in USA would mean an emission of three tonnes per capita by 2050. Reduction of 20 per cent in India would mean 0.8 tonnes per capita by 2050. Thus, the threat to the planet and civilisation caused, in the first place, by the advanced capitalist countries is now to be met by the victims of this pattern of development – the developing countries - by bearing a burden three times greater. This imperialist logic of `equality’ and `justice’ cannot be accepted. India must insist that the criteria of per capita emissions must be the basis for a solution
PLANET EARTH CRISIS DEEPENS
ONCE again, India’s ranking in the Human Development Index (HDI) has dropped. Last year, India ranked 126 amongst 177 countries. This year, the ranking has come down to 128, even behind Maldives. To be fair, however, India’s HDI value has grown marginally from 0.611 to 0.619. Yet, its lower rating is due to the fact that other developing countries have faired better. The report states: “While India is a high growth economy, the benefits have been unequally shared and there is a large human development backlog. Around 28 per cent of the population, some 320 million people live below the poverty line and three quarters of the poor are in rural areas.” With the continuing agrarian distress in the country, this only confirms what we have been stating in these columns regularly. Far from achieving “inclusive growth” as declared by the Eleventh Five Year Plan, two Indias are being created – the `shining’ and the `suffering’ – and the gap is widening.
The HDI is a summary measure monitoring long term progress in the average level of human development in three basic dimensions – a long and healthy life; access to knowledge; and, decent standard of living. These are measured by a series of quantitative data parameters.
The data in the report confirms the growing inequalities – between countries as well as within countries – between the rich and the poor in the phase of current globalisation. 40 per cent of world’s population living on less than $ 2 a day accounts for 5 per cent of global income while the richest 20 per cent accounts for three quarters of world income. More than 80 per cent of the world’s population lives in countries where income differentials are widening. Around ten million children die each year before the age of 5 and around 28 per cent of all children in the developing countries are undernourished.
This year’s HDR’s significance, however, lies in the fact that it has brought out an additional alarming dimension – climate change – which further accentuates this divide apart from threatening the very future of human civilisation. At the present rate the global temperature is expected to increase by 5 degrees Celsius in the 21st century, while the danger mark threatening life sustainability on the planet would be crossed at 2 degrees Celsius. If this is not arrested, then the worst sufferers would be 40 per cent of the world’s poor people – 2.6 billion.
Climate change occurs through the emission of greenhouse gases, mainly carbon dioxide that trap heat in the atmosphere. The current global release of such gases has exceeded the natural range of the last 650,000 years in the life of our planet. The main reason for this is the pattern of industrialisation, in pursuit of ever higher profits by capitalism, in the industrially-advanced countries. The carbon emission footprint of the USA is over 15 times that of India. If every person in the developing world were to have the same carbon footprint as one in USA or Canada, then the level of emissions would be 9 times higher than the limit required to sustain our planet.
Thus, the primary cause for bringing the world to such a disaster has been the predatory capriciousness of global capitalism. Not only have the developed countries enriched themselves at the expense of intensified exploitation of the developing world, but, ironically, the consequent climate change affects the people in the developing world most adversely.
Climate change will affect rainfall, temperature and water availability adversely affecting livelihood of billions dependent on agriculture in the world. Needless to add, India would be one of the worst sufferers. The melting of glaciers will affect the flows of river waters affecting the lives of billions of people. Particularly, the whole of South Asia would be affected with the retreat of the Himalayan glaciers. A 3-4 degree increase in the global temperature will displace millions due to flooding. The warming of the seas and land would lead to the extinction of one-third of our species.
The affects of such changes are already been felt. Some 262 million people had been adversely affected by climate disasters annually between 2000 and 2004. 98 per cent of these are in the developing countries. Out of every 1500 people affected, for instance, 1470 belong to the developing world while only one may belong to the industrially-developed countries. Such poor people are often forced to sell their productive assets or save on food, health and education, creating “life-long cycles of disadvantage”. Illustrating this, the report states: “Indian women born during a flood in the 1970s were 19 per cent less likely to have attended primary school.” Thus, the report warns: “Superimposing incremental climate change risks on (India’s) large human development deficit would compromise the ambition of inclusive growth.”
While the facts are startling and warrant immediate global attention and action, the proposals to tackle the situation have become controversial. The report prescribes a 50 per cent global reduction in greenhouse gas emissions by 2050 compared to the 1990 levels for a sustainable future. To achieve this, it suggests that the developed countries must cut their emissions by 30 per cent by 2020 growing to 80 per cent by 2050. The developing countries are being asked to reduce emissions by 20 per cent by 2050.
Under the Kyoto Protocol, which runs till 2012, the major thrust of reducing emissions was on the developed countries while the developing countries were exempted. This was naturally so because it is the developed world that is overwhelmingly responsible for triggering this climate change. True to its nature and with imperialist arrogance, the USA refused to ratify the Kyoto Protocol. This HDR report comes on the eve of a crucial summit on climate change at Bali which will deliberate and hopefully decide on these matters. Given US imperialism’s intransigence, it continues to refuse to take any responsibility for being the major plunderer of world’s resources and the largest carbon emitter.
Unlike this HDR report, which prescribes solutions on the basis of total global emissions, the Indian prime minister at the recent G-8 Summit in Germany proposed that per capita emissions must be the basis for a solution. For instance, India’s per capita emission is 17 times less than that of the USA. USA, today, emits around 20 tonnes per capita while India emits around one tonne per capita. Reducing 80 per cent in USA would mean an emission of three tonnes per capita by 2050. Reduction of 20 per cent in India would mean 0.8 tonnes per capita by 2050. Thus, the threat to the planet and civilisation caused, in the first place, by the advanced capitalist countries is now to be met by the victims of this pattern of development – the developing countries - by bearing a burden three times greater. This imperialist logic of `equality’ and `justice’ cannot be accepted. India must insist that the criteria of per capita emissions must be the basis for a solution
Friday, December 21, 2007
Tuesday, December 18, 2007
IMRANA CASE
Dear Doctor/Colleague
The Novartis, a Swiss Multinational pharmaceutical company operating in India,has challenged the order of the Patent Office in Chennai, rejecting its application for a patent on
IMATINIB MESYLATE which Novartis markets in India under the trade name Gleevec. In the second application filed in the Chennai High Court, Novartis had challenged the
constitutional validity of Section 3(d) of the Indian Patents Act by claiming that this section does not comply with the TRIPs agreement
It is a matter of grave concern that a foreign company chose to challenge the constitution ability of a law that has been passed by the Indian Parliamentto safeguard public health. Members of the medical profession need to be particularly concerned about such attempted misuse of use of Indian Legal System.
As you would know, Imatinib mesylate is extremely useful in the treatment of chronic myeloid leukemia (CML).
Treatment with Gleevec (manufactured and marketed by Novartis) costs rupees 1,20,000 per month, whereas Indian companies ( Cipla/Ranbaxy) market the same drug at a price of about Rs. 8,000 per month.
If a patent were to be granted to Novartis for imatinib mesylate, some Indian companies may be forced to stop production of the drug denying access to it to 99% of patients. It will open the floodgates for the MNC’s so that they too can apply for trivial patents.
Haryana Vigyan manch and Jan Sawasthaya Abhiyan Haryana appeal to you as a medical Professional to bycott products that are manufactured and marketed by Novartis by refraining from prescribing drugs that are marketed by Novartis.
The list is as follows:
List of medicines manufactured / marketed by Novartis in India
Brand Name Indication/Therapeutic Group Active Ingredient(s)
3-FD Anti-TB FDC INH + Rifampicin + Pyrazinamide
4-D Anti-TB FDC INH + Rifampicin + Pyrazinamide + Ethambutol
Adelphane Hypertension Reserpine + Dihydrallazine
Adelphane-Esidrex Hypertension Reserpine + Dihydrallazine + Hydrocholothiazide
Anafranil Antidepressant Clomipramine
Angicor Anti-anginal Isosorbide-5-Mononitrate
Antrenyl Peptic Ulcer/ Colicky pain Oxyphenonium Br
Aredia Bone disoders/ high calcium level Pamidronate
Aubril antimicrobial Sulfadiazine + Trimethoprim
Benace Hypertension Benazepril
Bradex-Vioform Anti-infective skin ointment Quinodochlor + Tripelennamine + Domiphen Br
Brinaldix Oedema of CCF, Renal or Hepatic failure Clopamide
Broadband Antimicrobial Gatifloxacin
Calcium–Sandoz Calcium deficiency Cal Glubionate
Clearance Opthalmic Naphazoline
Cletus Ant-platelet aggregation Cilostazol
Curam Antimicrobial Amoxicillin and Clavilonic acid
Daskil Antimicrobial Terbinafine
Desferal Acute iron poisoning Desferrioxamine
Dibimet Hypoglycaemic Metformin + starch and cellulose
Diovan Post MI with LVF Valsartan
Ebutol Anti-tuberculous Ethambutol
Epitril Tranqulizer/ anti-epileptic Clonazepam
Exelon Alzheimer’s Dementia Rivastigmine
Foristal Anti-allergic Dimethindene maleate
Genteal Opthalmic lubricant Boric acid, etc.
Glyred M Hypoglycaemic Metformin + Gliclazide + cellulose, starch and others
Hematrine Hematinic Ferrous suc, Succinic acid, Folic acid, Vit C, B-12, Nicotinamide
Hydergine Dementia Dihydroergotoxine
Hypotears plus Opthalmic Boric acid, CaCl2, MgCl
Leucomax Acceleration of myeloid recovery following bone marrow transplant GM-CSF
Liquidix SR Mucolytic Ambroxol
Lioresal Spastic conditions of skeletal muscles Baclofen
Lopresor Anti-hypettensive, etc. Metoprolol
Lodiric Anti-hyperuricaemic Allopurinal
Loromycin Antimicrobial Azithromycin
Macalvit Calcium supplement Cal glucono-galacto-gluconate, Cal lactbionate, Vit B-12, D-3
Methergin Post partum and post abortal bleeding Methylergometrine maleate
Miacalcic post menopausal osteoporosis Salmon calcitonin
Millicortenol Dermatitis (topical oint.) Dexamethasone
Millicorten-Vioform Anti-bacterial/ anti-fungal topical oint. Dexamethasone + Quiniodchlor
Nepresol Anti hypertensive Dihydrallazine sulphate
Nitroderm TTS Anti-anginal nitroglycerine in transdermal patch
Nutrisan Nutrional supplement Vit A, Vit D, B-1, B-2, Nicotinamide, B-6, Folic acid, C, Vit B-12, Ferrous fum, Mang chl, Mag oxide, Cal gluconate, Zinc oxide
Nyolol For treating glaucoma Timolol
Okacin Anti-bacterial opthalmic prep. Lomefloxacin
Otrivin Nasal decongestant Xylometazoline
PZA-Ciba Anti-tuberculous Pyrazinamide
Parlodel Parkinsonism/ Galactorrhea, etc. Bromocriptine
Regestrone Synthetic Progesterone prep. Norethisterone acetate
Resource Nutrional
Rimactane Anti-TB Rifampicin
Rimactazid-Z Anti-TB FDC Rifampicin, Isoniazid, Pyrazinamide
Rimastar Anti-TB FDC Ethambutal, INH, Pyrazinamide, Rifampicin
Rimicure 3FDC Anti-TB FDC Ethambutal, INH, Pyrazinamide, Rifampicin
Rimmax 2FDC Anti-TB FDC INH, Rifampicin
Rimthree FDC Anti-TB FDC Ethambutol, INH, Rifampicin
Rotacor Anti-hypercholesterlaemia Atorvastatin
Sandimmun Neoral Prevention of graft rejections Cyclosporine
Sandocal Vit. D Deficiency Vit D3, Cal carbonate
Sandostatin Relief of symptoms associated with gastroenteric-pancreatic endocrine tumors Octreotide
Santevini Tonic Thiamine mononit, Vit B-2, B-6, Niacinamide, Peptone, Cal gluconate
Secef Anti-microbial Cefixime
Sclerace Antihypertensive Rampril
Sirdalud Spasticity, trauma, cerebral palsy, etc. Tizanidine
Sintamil Anti-depressant Nitroxazepine
Spert Nutritional Protein supplement with vitamins and minerals
Sulcef Anti-microbial Cefoperazone + Sulbactan
Syntocinon PPH and acceleration of labour Oxytocin
Taregyl Antihistamine Clemastine
Tegritol Trigeminal Neuralgia Carbamazepine
Trioptal Anti-eplileptic Oxcarbazepine
Urclar Anti-microbial Clarithromycin
Visken Anti-anginal Pindolol
Voltaflam NSAID Diclofenac
Voveran NSAID Diclofenac
Zetri Anti-microbial Ceftriaxone
Zometa For tumor induced hypercalcaemia Zoledronic
Sincerely Yours
R.S. Dahiya Ved Pirya
President haryana vigyan manch Secretary ,Haryana Vigyan Manch
9812139001 9992132961
The Novartis, a Swiss Multinational pharmaceutical company operating in India,has challenged the order of the Patent Office in Chennai, rejecting its application for a patent on
IMATINIB MESYLATE which Novartis markets in India under the trade name Gleevec. In the second application filed in the Chennai High Court, Novartis had challenged the
constitutional validity of Section 3(d) of the Indian Patents Act by claiming that this section does not comply with the TRIPs agreement
It is a matter of grave concern that a foreign company chose to challenge the constitution ability of a law that has been passed by the Indian Parliamentto safeguard public health. Members of the medical profession need to be particularly concerned about such attempted misuse of use of Indian Legal System.
As you would know, Imatinib mesylate is extremely useful in the treatment of chronic myeloid leukemia (CML).
Treatment with Gleevec (manufactured and marketed by Novartis) costs rupees 1,20,000 per month, whereas Indian companies ( Cipla/Ranbaxy) market the same drug at a price of about Rs. 8,000 per month.
If a patent were to be granted to Novartis for imatinib mesylate, some Indian companies may be forced to stop production of the drug denying access to it to 99% of patients. It will open the floodgates for the MNC’s so that they too can apply for trivial patents.
Haryana Vigyan manch and Jan Sawasthaya Abhiyan Haryana appeal to you as a medical Professional to bycott products that are manufactured and marketed by Novartis by refraining from prescribing drugs that are marketed by Novartis.
The list is as follows:
List of medicines manufactured / marketed by Novartis in India
Brand Name Indication/Therapeutic Group Active Ingredient(s)
3-FD Anti-TB FDC INH + Rifampicin + Pyrazinamide
4-D Anti-TB FDC INH + Rifampicin + Pyrazinamide + Ethambutol
Adelphane Hypertension Reserpine + Dihydrallazine
Adelphane-Esidrex Hypertension Reserpine + Dihydrallazine + Hydrocholothiazide
Anafranil Antidepressant Clomipramine
Angicor Anti-anginal Isosorbide-5-Mononitrate
Antrenyl Peptic Ulcer/ Colicky pain Oxyphenonium Br
Aredia Bone disoders/ high calcium level Pamidronate
Aubril antimicrobial Sulfadiazine + Trimethoprim
Benace Hypertension Benazepril
Bradex-Vioform Anti-infective skin ointment Quinodochlor + Tripelennamine + Domiphen Br
Brinaldix Oedema of CCF, Renal or Hepatic failure Clopamide
Broadband Antimicrobial Gatifloxacin
Calcium–Sandoz Calcium deficiency Cal Glubionate
Clearance Opthalmic Naphazoline
Cletus Ant-platelet aggregation Cilostazol
Curam Antimicrobial Amoxicillin and Clavilonic acid
Daskil Antimicrobial Terbinafine
Desferal Acute iron poisoning Desferrioxamine
Dibimet Hypoglycaemic Metformin + starch and cellulose
Diovan Post MI with LVF Valsartan
Ebutol Anti-tuberculous Ethambutol
Epitril Tranqulizer/ anti-epileptic Clonazepam
Exelon Alzheimer’s Dementia Rivastigmine
Foristal Anti-allergic Dimethindene maleate
Genteal Opthalmic lubricant Boric acid, etc.
Glyred M Hypoglycaemic Metformin + Gliclazide + cellulose, starch and others
Hematrine Hematinic Ferrous suc, Succinic acid, Folic acid, Vit C, B-12, Nicotinamide
Hydergine Dementia Dihydroergotoxine
Hypotears plus Opthalmic Boric acid, CaCl2, MgCl
Leucomax Acceleration of myeloid recovery following bone marrow transplant GM-CSF
Liquidix SR Mucolytic Ambroxol
Lioresal Spastic conditions of skeletal muscles Baclofen
Lopresor Anti-hypettensive, etc. Metoprolol
Lodiric Anti-hyperuricaemic Allopurinal
Loromycin Antimicrobial Azithromycin
Macalvit Calcium supplement Cal glucono-galacto-gluconate, Cal lactbionate, Vit B-12, D-3
Methergin Post partum and post abortal bleeding Methylergometrine maleate
Miacalcic post menopausal osteoporosis Salmon calcitonin
Millicortenol Dermatitis (topical oint.) Dexamethasone
Millicorten-Vioform Anti-bacterial/ anti-fungal topical oint. Dexamethasone + Quiniodchlor
Nepresol Anti hypertensive Dihydrallazine sulphate
Nitroderm TTS Anti-anginal nitroglycerine in transdermal patch
Nutrisan Nutrional supplement Vit A, Vit D, B-1, B-2, Nicotinamide, B-6, Folic acid, C, Vit B-12, Ferrous fum, Mang chl, Mag oxide, Cal gluconate, Zinc oxide
Nyolol For treating glaucoma Timolol
Okacin Anti-bacterial opthalmic prep. Lomefloxacin
Otrivin Nasal decongestant Xylometazoline
PZA-Ciba Anti-tuberculous Pyrazinamide
Parlodel Parkinsonism/ Galactorrhea, etc. Bromocriptine
Regestrone Synthetic Progesterone prep. Norethisterone acetate
Resource Nutrional
Rimactane Anti-TB Rifampicin
Rimactazid-Z Anti-TB FDC Rifampicin, Isoniazid, Pyrazinamide
Rimastar Anti-TB FDC Ethambutal, INH, Pyrazinamide, Rifampicin
Rimicure 3FDC Anti-TB FDC Ethambutal, INH, Pyrazinamide, Rifampicin
Rimmax 2FDC Anti-TB FDC INH, Rifampicin
Rimthree FDC Anti-TB FDC Ethambutol, INH, Rifampicin
Rotacor Anti-hypercholesterlaemia Atorvastatin
Sandimmun Neoral Prevention of graft rejections Cyclosporine
Sandocal Vit. D Deficiency Vit D3, Cal carbonate
Sandostatin Relief of symptoms associated with gastroenteric-pancreatic endocrine tumors Octreotide
Santevini Tonic Thiamine mononit, Vit B-2, B-6, Niacinamide, Peptone, Cal gluconate
Secef Anti-microbial Cefixime
Sclerace Antihypertensive Rampril
Sirdalud Spasticity, trauma, cerebral palsy, etc. Tizanidine
Sintamil Anti-depressant Nitroxazepine
Spert Nutritional Protein supplement with vitamins and minerals
Sulcef Anti-microbial Cefoperazone + Sulbactan
Syntocinon PPH and acceleration of labour Oxytocin
Taregyl Antihistamine Clemastine
Tegritol Trigeminal Neuralgia Carbamazepine
Trioptal Anti-eplileptic Oxcarbazepine
Urclar Anti-microbial Clarithromycin
Visken Anti-anginal Pindolol
Voltaflam NSAID Diclofenac
Voveran NSAID Diclofenac
Zetri Anti-microbial Ceftriaxone
Zometa For tumor induced hypercalcaemia Zoledronic
Sincerely Yours
R.S. Dahiya Ved Pirya
President haryana vigyan manch Secretary ,Haryana Vigyan Manch
9812139001 9992132961
Friday, December 14, 2007
Health System in India-- Its weaknesses
Weakness of the Public
Health System in India
In India during British rule, state and philanthropic intervention played a significant role in healthcare, though most of these facilities were located in large towns, thus projecting a clear urban bias and neglect of the rural population. Modern medicine gradually undermined systems of Ayurveda and Unani, and those traditional practitioners who survived often concentrated in the small towns and rural areas where modern medicine had not yet penetrated. Despite the Bhore committee's recommendations at the dawn of independence towards correcting the rural-urban imbalance and suggestion of integrated planning for increasing access to health services, even postindependence the weakness of public health services in rural areas
and growth of private practice continued. Public health remained a low priority in successive five-year plans and public health efforts remained focused on specific vertical programmes, of which the Family Planning programme was the most prominent. This contributed to the slow and inadequate improvement in health of the population in the period from the 1950s to the 1970s. It may be noted that until 1983 India had no formal health policy; the planning process and various committees appointed from time to time provided most of the inputs for the formulation of health programme design.
This unsatisfactory situation was recognised in the National Health Policy of 1983, which was critical of the curative-oriented western, urban-based model of healthcare, and emphasised a primary healthcare approach. There were recommendations for preventive services and a decentralised system of healthcare, focusing on low expenditure, de-professionalisation (involvement of volunteers and paramedics) and community participation. Although, significant expansion of healthcare infrastructure did take place during the 1980s, this remained grossly underutilised because of poor facilities and low attendance by medical staff, inadequate supplies, insufficient hours, lack of community involvement and lack of proper monitoring mechanisms. The Primary Healthcare Approach was never implemented in its full form, and selective vertical programmes were pushed as a substitute for comprehensive health system development. This already unsatisfactory situation seriously worsened with the
onset of globalisation-liberalisation-privatisation from 1990s onwards. In this situation of inadequate and top-down development of public health, the impact of neo-liberal policies from the 1990s has precipitated the crisis of the public health system; there has been a retreat from even the nominal universal healthcare access objectives. Guided by prescriptions from agencies such as the World Bank, public healthcare has been further constricted to certain 'cost effective' preventive-promotive services and selective interventions, paralleled by spiraling and unregulated expansion of the private medical sector. Introduction of user fees at various levels of public health facilities has also been a feature of the phase since 1990s.
A new National Health Policy was announced in 2002, which acknowledged that the public healthcare system is grossly deficient on various fronts and resource allocations are generally insufficient. While this policy stated goals like "increase utilisation of public health facilities from current level of less than 20% to more than 75%", no corresponding large-scale measures for rejuvenating and strengthening the debilitated public health system were planned. In fact the 2002 NHP seems like a collection of unconnected statements, a dilution of the role of public health services and an unabashed promotion
of the private health sector, including 'medical tourism'. Thus the phase of privatisation-liberalisation has witnessed
staggering health inequities, resurgence of communicable diseases and an even more unregulated drug industry with drug prices shooting up, adding up to the current crisis in public health. Along with the retreat from the goal of universal access, special health needs of women, children and other sections of society with special needs have become further sidelined or are inadequately addressed. A much overdue response to this situation, with certain positive features but beset with its own contradictions, was launched in the form of NRHM in 2005, which is discussed in a separate section below.
To summarise, the objective of universal access to good quality, appropriate healthcare, envisaged over half a century ago at the dawn of Independence, today remains unrealised. Public health has effectively remained a low priority for the Indian state in terms of financing and political attention. Consequently, there has been a major and growing divergence between the policy rhetoric (such as the Alma Ata Declaration) and actual implementation. Moving in to occupy the hiatus, there has been a massive growth of the private sector, which is unaffordable for a large section of the population, and which lacks any regulation and standardisation. Closely related to this, and compounding this situation has been a Techno-managerial model of healthcare inspired by the West, with an inability to evolve effective indigenous models and appropriate technologies, or to effectively integrate modern and indigenous systems of medicine in contrast to China. The system of Health planning and
decision making has remained highly centralised and top-down with minimal accountability, little decentralised planning or scope for genuine community initiatives. A prime example of this is the various communicable disease control programmes that are discussed separately in a later section.Now, to better understand the lopsided development of the health system, we will first take a look at financingof healthcare in India.
R.S.Dahiya
Health System in India
In India during British rule, state and philanthropic intervention played a significant role in healthcare, though most of these facilities were located in large towns, thus projecting a clear urban bias and neglect of the rural population. Modern medicine gradually undermined systems of Ayurveda and Unani, and those traditional practitioners who survived often concentrated in the small towns and rural areas where modern medicine had not yet penetrated. Despite the Bhore committee's recommendations at the dawn of independence towards correcting the rural-urban imbalance and suggestion of integrated planning for increasing access to health services, even postindependence the weakness of public health services in rural areas
and growth of private practice continued. Public health remained a low priority in successive five-year plans and public health efforts remained focused on specific vertical programmes, of which the Family Planning programme was the most prominent. This contributed to the slow and inadequate improvement in health of the population in the period from the 1950s to the 1970s. It may be noted that until 1983 India had no formal health policy; the planning process and various committees appointed from time to time provided most of the inputs for the formulation of health programme design.
This unsatisfactory situation was recognised in the National Health Policy of 1983, which was critical of the curative-oriented western, urban-based model of healthcare, and emphasised a primary healthcare approach. There were recommendations for preventive services and a decentralised system of healthcare, focusing on low expenditure, de-professionalisation (involvement of volunteers and paramedics) and community participation. Although, significant expansion of healthcare infrastructure did take place during the 1980s, this remained grossly underutilised because of poor facilities and low attendance by medical staff, inadequate supplies, insufficient hours, lack of community involvement and lack of proper monitoring mechanisms. The Primary Healthcare Approach was never implemented in its full form, and selective vertical programmes were pushed as a substitute for comprehensive health system development. This already unsatisfactory situation seriously worsened with the
onset of globalisation-liberalisation-privatisation from 1990s onwards. In this situation of inadequate and top-down development of public health, the impact of neo-liberal policies from the 1990s has precipitated the crisis of the public health system; there has been a retreat from even the nominal universal healthcare access objectives. Guided by prescriptions from agencies such as the World Bank, public healthcare has been further constricted to certain 'cost effective' preventive-promotive services and selective interventions, paralleled by spiraling and unregulated expansion of the private medical sector. Introduction of user fees at various levels of public health facilities has also been a feature of the phase since 1990s.
A new National Health Policy was announced in 2002, which acknowledged that the public healthcare system is grossly deficient on various fronts and resource allocations are generally insufficient. While this policy stated goals like "increase utilisation of public health facilities from current level of less than 20% to more than 75%", no corresponding large-scale measures for rejuvenating and strengthening the debilitated public health system were planned. In fact the 2002 NHP seems like a collection of unconnected statements, a dilution of the role of public health services and an unabashed promotion
of the private health sector, including 'medical tourism'. Thus the phase of privatisation-liberalisation has witnessed
staggering health inequities, resurgence of communicable diseases and an even more unregulated drug industry with drug prices shooting up, adding up to the current crisis in public health. Along with the retreat from the goal of universal access, special health needs of women, children and other sections of society with special needs have become further sidelined or are inadequately addressed. A much overdue response to this situation, with certain positive features but beset with its own contradictions, was launched in the form of NRHM in 2005, which is discussed in a separate section below.
To summarise, the objective of universal access to good quality, appropriate healthcare, envisaged over half a century ago at the dawn of Independence, today remains unrealised. Public health has effectively remained a low priority for the Indian state in terms of financing and political attention. Consequently, there has been a major and growing divergence between the policy rhetoric (such as the Alma Ata Declaration) and actual implementation. Moving in to occupy the hiatus, there has been a massive growth of the private sector, which is unaffordable for a large section of the population, and which lacks any regulation and standardisation. Closely related to this, and compounding this situation has been a Techno-managerial model of healthcare inspired by the West, with an inability to evolve effective indigenous models and appropriate technologies, or to effectively integrate modern and indigenous systems of medicine in contrast to China. The system of Health planning and
decision making has remained highly centralised and top-down with minimal accountability, little decentralised planning or scope for genuine community initiatives. A prime example of this is the various communicable disease control programmes that are discussed separately in a later section.Now, to better understand the lopsided development of the health system, we will first take a look at financingof healthcare in India.
R.S.Dahiya
JAN SAWASTHAYA ABHIYAN
Jan Swasthya Abhiyan
In 1978 at Alma Ata, the governments of the world came together to sign the
Alma Ata Declaration that promised "Health for All by 2000". However this
promise was never taken very seriously and was subsequently marginalised in
health policy discussions.
As the year 2000 approached it appeared that "Health for All by 2000"
was quietly being forgotten by governments around the world. To remind
people of this forgotten commitment the First People's Health Assembly
was organised in Savar, Bangladesh in December 2000 . The People's Health
Assembly was a coming together of people's movements and other nongovernment
civil society organisations all over the world to reiterate the pledge
for Health for All and to make governments take this promise seriously. The
assembly also aimed to build global solidarity, and to bring together people's
movements and organisations working to advance the people's health in the
context of policies of globalisation.
The national networks and organisations that had come together to
organize the National Health Assembly, decided to continue and develop this
movement in the form of the Jan Swasthya Abhiyan (People's Health
Movement). Jan Swasthya Abhiyan forms the Indian regional circle of the
global People's Health Movement..
Despite medical advances and increasing average life expectancy, there is
disturbing evidence of rising disparities in health status among people
worldwide. Enduring poverty with all its facets and in addition, resurgence of
communicable diseases including the HIV/AIDS epidemic, and weakening
of public health systems is leading to reversal of previous health gains. This
development is associated with widening gaps in income and shrinking access
to social services, as well as persistent racial and gender imbalances. Traditional
systems of knowledge and health are under threat.
These trends are to a large extent the result of the inequitable structure
of the world economy, which has been further skewed by structural adjustment
policies, the persistent indebtedness of the South, unfair world trade
arrangements and uncontrolled financial speculation - all part of the rapid
movement towards inequitable globalisation. In many countries, these
problems are compounded by lack of coordination between governments
and international agencies, and stagnant or declining public health budgets.
Within the health sector, failure to implement primary health care policies as
originally conceived has significantly aggravated the global health crisis. These
deficiencies include:
• A retreat from the goal of comprehensive national health and drug polices as
part of overall social policy.
• A lack of insight into the inter-sectoral nature of health problems and the
failure to make health a priority in all sectors of society.
• A failure to promote participation and genuine involvement of communities
in their own health development.
• Reduced state responsibility at all levels as a consequence of widespread and
usually inequitable policies of privatisation of health services.
• A narrow, top-down, technology-oriented view of health and increasingly
viewing health care as a commodity rather than as a human right.
• It is with this perspective that the organisations constituting the Jan Swasthya
Abhiyan have come together to launch a movement, emerging from the
Peoples Health Assembly process. Some objectives that this coalition set for
itself (which are set out in detail in the Peoples Health Charter) can be listed
briefly as below:
• The Jan Swasthya Abhiyan aims to draw public attention to the adverse
impact of the policies of iniquitous globalisation on the health of Indian
people, especially on the health of the poor.
• The Jan Swasthya Abhiyan aims to focus public attention on the passing of
the year 2000 without the fulfillment of the 'Health for All by 2000 A.D.'
pledge. This historic commitment needs to be renewed and taken forward,
with the slogan 'Health for All - Now!' and in the form of the campaign to
establish the Right to Health and Health Care as basic human rights. Health
and equitable development need to be reestablished as priorities in local,
national, international policy-making, with Primary Health Care as a major
strategy for achieving these priorities.
• In India, globalisation's thrust for privatisation and retreat of the state with
poor regulatory mechanisms has exacerbated the trends to commercialise
medical care. Irrational, unethical and exploitative medical practices are flourishing
and growing. The Jan Swasthya Abhiyan expresses the need to confront
such commercialisation, while establishing minimum standards and
rational treatment guidelines for health care.
• In the Indian context, top down, bureaucratic, fragmented techno-centric
approaches to health care have created considerable wastage of scarce resources
and have failed to deliver significant health improvements. The Jan Swasthya
Abhiyan seeks to emphasize the urgent need to promote decentralisation of
health care and build up integrated, comprehensive and participatory approaches
to health care that places "Peoples Health in Peoples Hands".
The Jan Swasthya Abhiyan seeks to network with all those interested in
promoting peoples' health. It seeks to unleash a wide variety of people's
initiatives that would help the poor and the marginalised to organise and
access better health care, while contributing to building long-term and
sustainable solutions to health problems
The Jan Swasthya Abhiyan is being coordinated by National Coordination
Committee consisting of 21 major all India networks of peoples movements
and NGOs.
R.S.Dahiya
Disparities
Disparities
v Social and Economics inequalities give birth to inequalities in health Inspite of great improvement in Global health in last four decades, the difference in infant mortality rate
between 26 Richest countries and 46 most undeveloped countries is 16 times.
Ø Out of 6 Arab estimated population of the world, about 3 Arab people are surviving on less than 2 dollar per day expenditure.
v Out of these 3 Arab, 1 Arab 30 crores survive on 1 dollar per day expenditure.
Ø Daily 84 crore people are sleeping hungry.
v In the poorest 46 countries half of their people do not get Modern Health facilities
Ø 3 Arab people do not have sanitation facilities.
v The Difference of per capita income between the richest and poorest countries was 11:1 in 1870 was 38:1 in 1960 and 53:1 in 1985
Ø 3 hours expenditure of the world’s defence is equal to WHO Annual Budget.
v With 3 weeks world’s expenditure on armaments the whole population of poor countries can be provided safe drinking waterand sanitation and primary health care.
R.S.Dahiya
v Social and Economics inequalities give birth to inequalities in health Inspite of great improvement in Global health in last four decades, the difference in infant mortality rate
between 26 Richest countries and 46 most undeveloped countries is 16 times.
Ø Out of 6 Arab estimated population of the world, about 3 Arab people are surviving on less than 2 dollar per day expenditure.
v Out of these 3 Arab, 1 Arab 30 crores survive on 1 dollar per day expenditure.
Ø Daily 84 crore people are sleeping hungry.
v In the poorest 46 countries half of their people do not get Modern Health facilities
Ø 3 Arab people do not have sanitation facilities.
v The Difference of per capita income between the richest and poorest countries was 11:1 in 1870 was 38:1 in 1960 and 53:1 in 1985
Ø 3 hours expenditure of the world’s defence is equal to WHO Annual Budget.
v With 3 weeks world’s expenditure on armaments the whole population of poor countries can be provided safe drinking waterand sanitation and primary health care.
R.S.Dahiya
Subscribe to:
Posts (Atom)














